Barriers to Herpes Zoster Vaccination
Authors: Laura Hurley
Journal: Annals of Internal Medicine (2010)

Letters21 September 2010Barriers to Herpes Zoster VaccinationLaura Hurley, MD, MPH and Allison Kempe, MD, MPHLaura Hurley, MD, MPHFrom Denver Health, Denver, CO 80204, and Colorado Health Outcomes Research Program, Aurora, CO 80045.Search for more papers by this author and Allison Kempe, MD, MPHFrom Denver Health, Denver, CO 80204, and Colorado Health Outcomes Research Program, Aurora, CO 80045.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-153-6-201009210-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We thank Dr. Opstelten and colleagues for their comments and agree that solving the financial and freezer storage issues we discovered would not remove all barriers to herpes zoster vaccine uptake in the United States. However, the results of our study and those of Opstelten and colleagues' study (1) differ in a few important ways that make direct comparison problematic. First, Opstelten and colleagues' study was done in the Netherlands, and the herpes zoster vaccine was not recommended there at that time; therefore, physicians and patients were probably not familiar with it. Our study was done in the ...References1. Opstelten W, van Essen GA, Hak E. Determinants of non-compliance with herpes zoster vaccination in the community-dwelling elderly. Vaccine. 2009;27:192-6. [PMID: 18996427] CrossrefMedlineGoogle Scholar2. Lu PJ, Euler GL, Jumaan AO, Harpaz R. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine. 2009;27:882-7. [PMID: 19071175] CrossrefMedlineGoogle Scholar3. Gilderman LI, Lawless JF, Nolen TM, Sterling T, Rutledge RZ, Fernsler DA, et al; Zostavax Protocol 010 Study Group. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clin Vaccine Immunol. 2008;15:314-9. [PMID: 18077611] CrossrefMedlineGoogle Scholar4. Kreth HW, Lee BW, Kosuwon P, Salazar J, Gloriani-Barzaga N, Bock HL, et al. Sixteen years of global experience with the first refrigerator-stable varicella vaccine (Varilrix). BioDrugs. 2008;22:387-402. [PMID: 18998756] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Laura Hurley, MD, MPH; Allison Kempe, MD, MPHAffiliations: From Denver Health, Denver, CO 80204, and Colorado Health Outcomes Research Program, Aurora, CO 80045.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoBarriers to the Use of Herpes Zoster Vaccine Laura P. Hurley , Megan C. Lindley , Rafael Harpaz , Shannon Stokley , Matthew F. Daley , Lori A. Crane , Fran Dong , Brenda L. Beaty , Litjen Tan , Christine Babbel , L. Miriam Dickinson , and Allison Kempe Barriers to Herpes Zoster Vaccination Wim Opstelten , Gerrit A. van Essen , and Eelko Hak Metrics 21 September 2010Volume 153, Issue 6Page: 418-419KeywordsConflicts of interestHealth careVaccines ePublished: 21 September 2010 Issue Published: 21 September 2010 Copyright & PermissionsCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...